News and Trends 10 Dec 2021 European Biotech Investors Cap Off Record Year in Fundraising The year 2021 is closing with a biotech investment rush as Eir Ventures, Apollo Health Ventures, and Merck’s venture capital arm M Ventures raise impressive funds to speed up life sciences innovation. This year is set to break records in terms of the money flowing into institutional life science investors. With 2021 not even finished, […] December 10, 2021 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jul 2021 Multi-Million UK Life Sciences Initiative Welcomed By VC Firms Biotech venture capital firms across Europe have warmly received the launch of a €235M (£200M) UK government initiative to support the growth of promising late-stage life sciences companies. The UK’s Life Sciences Investment Programme opened to applications from fund managers this month, with the aim of providing €235M in late-stage capital and attracting at least […] July 16, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Interview 16 Jan 2019 The Coming of Age of Biotechnology Since its beginnings in the 1970s, the biotech industry has grown massively and made huge advances. At our recent Labiotech Refresh in London, Tim Haines, Managing Partner at the life science VC Abingworth, shared his views on how biotechnology has finally come of age. Haines knows the biotech industry well. After leading and helping sell […] January 16, 2019 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jul 2018 Abingworth Closes €268M to Invest in Life Science Companies Abingworth has closed $315M (€268M) for its most recent fund, Abingworth Bioventures VII, which invests in European and US life science companies. In the current fundraising, Abingworth surpassed its target of $300M. The new fund will invest in life science companies in all stages of development, including early and late-stage venture deals. The company plans to […] July 9, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2016 Abingworth launches UK Immuno-Oncology Startup with Seed Funding Just when we thought it couldn’t become any more intense, the field of immuno-oncology is heating up. VC giant Abingworth has seeded a new UK startup, GammaDelta Therapeutics, to bring its T cell therapy to the clinic. Abingworth, a huge British VC firm, has thrown its weight behind a new London-based immuno-oncology startup, GammaDelta Therapeutics. […] September 19, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email